Skip to main content

Advertisement

SpringerLink
Log in

Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

High blood glucose levels may decrease the sensitivity of 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET). The goal of this study was to assess whether intravenous (i.v.) insulin followed by FDG injection 60 minutes later could decrease the blood glucose level of hyperglycemic patients without altering muscular, liver, or lung FDG uptake.

Methods

We evaluated 53 diabetic patients with a fasting glycemia higher than 7.0 mmol/l. The control group consisted of 53 nondiabetic patients with a normal fasting glycemia. Sixty minutes before FDG injection, all diabetic patients received up to two intravenous bolus of insulin. Regions of interest were drawn over the lungs, heart, liver, skeletal muscles, and over the most active lung nodule, if present, to calculate a standardized uptake value (SUV) normalized to the lean body weight.

Results

After one or two boluses of insulin (mean 3.4 units), 39 diabetic patients decreased their blood glucose level from 9.4 ± 1.8 to 6.1 ± 1.3 mmol/l. In 14 patients, two doses of insulin (mean 4.5 ± 2.3 units) were not sufficient, but managed to decrease the blood glucose level from 10.6 ± 2.1 to 9.1 ± 2.1 mmol/l. There was no significant difference for the SUV calculated on the lung, liver, heart, and skeletal muscles. No differences were noted in lung tumor uptake in patients who received insulin compared to the control group.

Conclusions

With a sufficient waiting period between the insulin and FDG injections, an i.v. bolus of insulin makes it possible to effectively decrease glycemia of diabetic patients without increasing muscular FDG uptake.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hustinx R, Benard F, Alavi A (2002) Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32(1):35–46

    Article  PubMed  Google Scholar 

  2. Diederichs CG, Staib L, Glatting G, et al. (1998) FDG-PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39(6):1030–1033

    CAS  PubMed  Google Scholar 

  3. Lindholm P, Minn H, Leskinen-Kallio S, et al. (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34(1):1–6

    CAS  PubMed  Google Scholar 

  4. Torizuka T, Fisher SJ, Brown RS, et al. (1998) Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology 208(2):499–504

    CAS  PubMed  Google Scholar 

  5. Wahl RL, Henry CA, Ethier SP (1992) Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology 183(3):643–647

    CAS  PubMed  Google Scholar 

  6. Lewis P, Nunan T, Dynes A, et al. (1996) The use of low-dose intravenous insulin in clinical myocardial F-18 FDG-PET scanning. Clin Nucl Med 21(1):15–18

    Article  CAS  PubMed  Google Scholar 

  7. Sherwin RS, Kramer KJ, Tobin JD, et al. (1974) A model of the kinetics of insulin in man. J Clin Invest 53(5):1481–1492

    Article  CAS  PubMed  Google Scholar 

  8. Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26(4):292–307

    CAS  PubMed  Google Scholar 

  9. Medina RA, Owen GI (2002) Glucose transporters: expression, regulation and cancer. Biol Res 35(1):9–26

    Article  CAS  PubMed  Google Scholar 

  10. Marom EM, Aloia TA, Moore MB, et al. (2001) Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33(2–3):99–107

    Article  CAS  PubMed  Google Scholar 

  11. Langen KJ, Braun U, Rota Kops E, et al. (1993) The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34(3):355–359

    CAS  PubMed  Google Scholar 

  12. Crippa F, Gavazzi C, Bozzetti F, et al. (1997) The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori 83(4):748–752

    CAS  PubMed  Google Scholar 

  13. Torizuka T, Zasadny KR, Wahl RL (1999) Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imaging 2(5):281–287

    Article  PubMed  Google Scholar 

  14. Gorenberg M, Hallett WA, O’Doherty MJ (2002) Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging 29(10):1324–1327

    Article  CAS  PubMed  Google Scholar 

  15. Chang YC, Yen TC, Ng KK, et al. (2005) Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer? Eur J Nucl Med Mol Imaging 32(6):647–652

    Article  PubMed  Google Scholar 

  16. Torizuka T, Fisher SJ, Wahl RL (1997) Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-d-glucose into experimental mammary carcinoma. Radiology 203(1):169–172

    CAS  PubMed  Google Scholar 

  17. Zhao S, Kuge Y, Tsukamoto E, et al. (2001) Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med 28(6):730–735

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, 3001, 12th Ave N., Sherbrooke, QC, Canada, J1H 5N4

    Eric Turcotte MD, Michel Leblanc MD & François Bénard MD

  2. Division of Endocrinology and metabolism, Department of Medicine, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

    André Carpentier MD

Authors
  1. Eric Turcotte MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Leblanc MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. André Carpentier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. François Bénard MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Bénard MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turcotte, E., Leblanc, M., Carpentier, A. et al. Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients. Mol Imaging Biol 8, 348–354 (2006). https://doi.org/10.1007/s11307-006-0064-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-006-0064-1

Key words

Search

Navigation